MEF2A and colorectal carcinoma: Abnormal expression or mutation of MEF2 is closely associated with the progression of various tumors, such as large B-cell lymphoma [6], leukemia [7], and certain solid tumors (hepatocellular carcinoma [8] and CRC [9]).